BCYC Stock Analysis: Buy, Sell, or Hold?
BCYC - Bicycle Therapeutics plc American Depositary Shares
$4.37
0.13 (3.07%)
▲
5d:
+12.05%
30d:
+5.05%
90d:
-1.8%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When BCYC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BCYC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BCYC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: BCYC is currently trading at $4.37, which is considered extended relative to its 30-day fair value range of $3.92 to $4.19.
Technical Outlook: Technically, BCYC is in a strong downtrend. Immediate support is located at $3.87, while resistance sits at $4.51. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: BCYC scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+117.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCYC is in a strong downtrend. Immediate support is located at $3.87, while resistance sits at $4.51. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: BCYC scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $9.50 (+117.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$3.92 -
$4.19
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 117.4% below Wall St target ($9.50)
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.92 -
$4.19
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$3.87
Resistance Level
$4.51
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.97
Wall Street Target
$9.50
(+117.4%)
Revenue Growth (YoY)
-78.5%
Share & Embed Analysis
Last updated: August 24, 2026 12:52 AM ET
Data refreshes hourly during market hours. Next update: 1:52 AM
Data refreshes hourly during market hours. Next update: 1:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCYC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin Lee
SELL
1716 shares
2026-04-06
Travis Alvin Thompson
SELL
102 shares
2026-04-06
Jennifer Scott Perry
SELL
370 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
